---
title: 'The MURANO study: final analysis and retreatment/crossover substudy results
  of VenR for patients with relapsed/refractory CLL'
date: '2025-02-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/40009494/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250227170931&v=2.18.0.post9+e462414
source: Blood
description: Fixed-duration venetoclax-rituximab (VenR) in patients with relapsed/refractory
  chronic lymphocytic leukemia (CLL) in the phase 3 MURANO trial (NCT02005471) resulted
  in superior progression-free survival (PFS) and overall survival (OS) vs bendamustine-rituximab
  (BR). We report the final analyses of MURANO (median 7 years follow-up). Patients
  were randomized to VenR (venetoclax 400 mg daily for 2 years plus monthly rituximab
  for 6 months; n = 194) or BR (6 months; n = 195). In a ...
disable_comments: true
---
Fixed-duration venetoclax-rituximab (VenR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) in the phase 3 MURANO trial (NCT02005471) resulted in superior progression-free survival (PFS) and overall survival (OS) vs bendamustine-rituximab (BR). We report the final analyses of MURANO (median 7 years follow-up). Patients were randomized to VenR (venetoclax 400 mg daily for 2 years plus monthly rituximab for 6 months; n = 194) or BR (6 months; n = 195). In a ...